Latest Insider Transactions at Dicerna Pharmaceuticals Inc (DRNA)
This section provides a real-time view of insider transactions for Dicerna Pharmaceuticals Inc (DRNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Dicerna Pharmaceuticals Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Dicerna Pharmaceuticals Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,973
-100.0%
|
$264,974
$38.25 P/Share
|
|
Dec 28
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,367
-100.0%
|
$89,946
$38.25 P/Share
|
|
Dec 28
2021
|
J Kevin Buchi Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,666
-100.0%
|
$177,308
$38.25 P/Share
|
|
Dec 28
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,813
-100.0%
|
$562,894
$38.25 P/Share
|
|
Dec 28
2021
|
Stephen K Doberstein Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
Douglas Fambrough Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
231,431
-100.0%
|
$8,794,378
$38.25 P/Share
|
|
Dec 28
2021
|
Martin I Freed Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
Patrick M. Gray Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
Stephen J Hoffman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,157
-100.0%
|
$613,966
$38.25 P/Share
|
|
Dec 28
2021
|
Marc D Kozin Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,000
-100.0%
|
$190,000
$38.25 P/Share
|
|
Dec 28
2021
|
Marc D Kozin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,333
-100.0%
|
$240,654
$38.25 P/Share
|
|
Dec 28
2021
|
Douglas W. Pagan Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,775
-100.0%
|
$295,450
$38.25 P/Share
|
|
Dec 28
2021
|
Cynthia Smith Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
18,100
-100.0%
|
$687,800
$38.25 P/Share
|
|
Dec 28
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,032
-100.0%
|
$191,216
$38.25 P/Share
|
|
Dec 28
2021
|
Adam Koppel Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,080,237
-100.0%
|
$117,049,006
$38.25 P/Share
|
|
Dec 28
2021
|
Adam Koppel Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 15
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-13.0%
|
$28,576
$38.05 P/Share
|
|
Dec 15
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
BUY
Exercise of conversion of derivative security
|
Direct |
2,562
+30.7%
|
-
|
|
Dec 15
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
1,675
-41.44%
|
$63,650
$38.05 P/Share
|
|
Dec 15
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
3,775
+48.29%
|
-
|
|
Dec 15
2021
|
Douglas Fambrough Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,348
-2.26%
|
$203,224
$38.05 P/Share
|
|
Dec 15
2021
|
Douglas Fambrough Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,750
+5.49%
|
-
|
|
Dec 15
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,675
-8.47%
|
$63,650
$38.05 P/Share
|
|
Dec 15
2021
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
3,775
+16.03%
|
-
|
|
Dec 15
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
833
-10.67%
|
$31,654
$38.05 P/Share
|
|
Dec 15
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,837
+26.66%
|
-
|
|
Dec 15
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,241
-7.73%
|
$47,158
$38.05 P/Share
|
|
Dec 15
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,425
+17.58%
|
-
|
|
Dec 15
2021
|
Douglas W. Pagan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
602
-7.19%
|
$22,876
$38.05 P/Share
|
|
Dec 15
2021
|
Douglas W. Pagan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,050
+19.66%
|
-
|
|
Dec 13
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,856
+41.22%
|
$194,832
$22.58 P/Share
|
|
Dec 10
2021
|
Douglas Fambrough Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
179,865
+35.03%
|
$539,595
$3.2 P/Share
|
|
Nov 18
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
24,936
-98.94%
|
$922,632
$37.94 P/Share
|
|
Nov 18
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
24,936
+49.73%
|
$74,808
$3.42 P/Share
|
|
Sep 17
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
21,250
-98.76%
|
$446,250
$21.06 P/Share
|
|
Sep 17
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,056
-29.27%
|
$43,176
$21.47 P/Share
|
|
Sep 17
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
SELL
Open market or private sale
|
Direct |
1,334
-29.28%
|
$28,014
$21.47 P/Share
|
|
Sep 15
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,025
+50.0%
|
-
|
|
Sep 15
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
BUY
Exercise of conversion of derivative security
|
Direct |
4,556
+50.0%
|
-
|
|
Aug 10
2021
|
Marc D Kozin Director |
BUY
Open market or private purchase
|
Direct |
3,000
+32.14%
|
$69,000
$23.66 P/Share
|
|
Aug 10
2021
|
Douglas Fambrough Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+10.38%
|
$110,000
$22.1 P/Share
|
|
Aug 02
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
8,312
-27.87%
|
$307,544
$37.38 P/Share
|
|
Aug 02
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,312
+21.79%
|
$24,936
$3.42 P/Share
|
|
Jul 06
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Open market or private sale
|
Direct |
30,000
-65.22%
|
$1,170,000
$39.09 P/Share
|
|
Jul 06
2021
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+39.47%
|
$270,000
$9.09 P/Share
|
|
Jul 06
2021
|
Regina M. Paglia Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,404
-40.92%
|
$51,948
$37.05 P/Share
|
|
Jul 06
2021
|
Regina M. Paglia Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,162
+39.52%
|
-
|
|
Jul 01
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
8,312
-14.51%
|
$307,544
$37.57 P/Share
|
|
Jul 01
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,312
+21.79%
|
$24,936
$3.42 P/Share
|